首页> 外文会议>Trends in Radiopharmaceuticals(ISTR-2005) >Role of radionuclide therapy as adjuvant to palliative external beamradiotherapy for painful multiple skeletal metastasis
【24h】

Role of radionuclide therapy as adjuvant to palliative external beamradiotherapy for painful multiple skeletal metastasis

机译:放射性核素治疗作为姑息性体外放射治疗疼痛多发性骨转移的佐剂

获取原文
获取外文期刊封面目录资料

摘要

Purpose: Aim of this study was to evaluate the palliative efficacy of localized external radiotherapycombined with systemic radionuclide therapy in patients who had multiple painful osseous metastases ofdifferent primary origins. 33 patients with painful multiple bone metastases from different primarily originswere eligible for this trial. Initially, local external radiotherapy was delivered to the most symptomatic region inall patients, followed by either Re186HEDP or Sm153EDTMP. The patients' mean age was 58.8 (min 35- max 82).The performance status was assessed acording to ECOG scale. Before treatment, at the end of the radiotherapyand after the 4 weeks of systemic radionuclide therapy, analgesic intake and pain status were recorded by theRTOG scoring system. In addition, the EORTC QLQ C30 (vesion 3.0 Turkish) questionnaire was performed toevaluate the quality of life at the start of treatment, at the end of the radiotherapy and after the 4 weeks ofsystemic radionuclide therapy. Improved performances of 33.3% for post radiation therapy and 50% for postradionuclide therapy in the ECOG scale were observed. Statistically significant correlations were found betweenthe primary origins and decreased pain and analgesic intake (p< 0.05), but no differences were observed on theself assesment quality of life questionnaire. Toxicity was acceptable. Overall median survival was 17 months,and progression free survival was 10 months. Patients with breast and prostate tumors had a higher overall andprogression free survival than those with other primary tumors (p=0.0062, p=0.0080). The results of this studydemonstrate that; both Re186HEDP and Sm153EDTMP are effective and safe in bone pain palliation as anadjuvant to local field radiation therapy of breast and prostate cancer patients, who also continued to receivechemotherapy and/or hormontherapy. This combined treatment may be an alternative to half body irradiation formultiple painful skeletal metastasis .
机译:目的:本研究的目的是评估局部外部放疗的姑息疗效 合并全身放射性骨转移性疼痛的患者联合全身放射性核素治疗 不同的主要起源。 33例来自不同起源的疼痛性多发性骨转移患者 有资格参加此审判。最初,当地的外部放射治疗被送到了症状最严重的地区。 所有患者,其次是Re186HEDP或Sm153E​​DTMP。患者的平均年龄为58.8(最小35-最大82)。 根据ECOG量表评估绩效状态。治疗前,放疗结束时 在进行了4周的全身放射性核素治疗后,记录了镇痛剂的摄入量和疼痛状态。 RTOG评分系统。此外,还进行了EORTC QLQ C30(3.0版土耳其语)问卷调查,目的是 在治疗开始时,放疗结束时和放疗4周后评估生活质量 全身放射性核素治疗。放射治疗后的性能提高了33.3%,放射后的性能提高了50% 观察到ECOG等级的放射性核素治疗。发现之间存在统计学上的显着相关性 主要起源和疼痛和止痛药摄入减少(p <0.05),但在 自我评估生活质量问卷。毒性是可以接受的。总体中位生存期为17个月, 无进展生存期为10个月。患有乳腺和前列腺肿瘤的患者的总体和 无进展生存率高于其他原发性肿瘤(p = 0.0062,p = 0.0080)。这项研究的结果 证明Re186HEDP和Sm153E​​DTMP均可有效且安全地缓解骨痛。 乳腺癌和前列腺癌患者的局部野外放射治疗的辅助药物,这些患者也继续接受治疗 化学疗法和/或激素疗法。这种联合治疗可以替代半身照射 多发性疼痛的骨骼转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号